initial public offerings (IPOs) trading on American exchanges

Sunday, October 22, 2017

TerraForm Power (TERP) : 3-year performance

Sector: Utilities > Industry: Renewable Utilities
  • Brookfield Renewable Partners L.P. (BEP) announced that, together with its institutional partners, it has closed the previously-announced acquisition of a 51% interest in TerraForm Power (TERP), a large scale, diversified portfolio of solar and wind assets located predominantly in the U.S., for a total commitment of $656 million.


** monthly **



TerraForm Power, Inc. is a United States-based holding company. The Company owns clean power generation assets. This includes solar and wind assets located in the United States, Canada and other markets. Its clean power generation assets serve utility, commercial and residential customers. As of December 31, 2016, the Company's portfolio consisted of renewable energy facilities located in the United States, Canada, the United Kingdom and Chile with a combined nameplate capacity of 2,983.1 megawatts. It owns and operates over 500 hundred wind and solar clean energy power installations. Its projects include Bluebird, River Mountains Solar, Laho Solar, SunE Perpetual Lindsday, Sandringham, California Public institutions and Summit Solar Projects. The Company holds interest in TerraForm Power, LLC (Terra LLC), which is an owner and operator of renewable energy facilities that have long-term contractual arrangements to sell the electricity generated by these facilities to third parties.

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin-0.40%-36.90%
Operating margin15.00%13.43%
EBITD margin-63.55%
Return on average assets-0.04%-3.03%
Return on average equity1.68%-10.98%

Saturday, October 21, 2017

CyrusOne (CONE) : 4-year performance

Data center REIT.   The company owns 35 operating data center facilities in 11 markets.
  • Headquarters: Dallas, TX
  • Founded 2001;  IPO in Jan 2013



CyrusOne Inc. is a real estate investment trust. The Company is an owner, operator and developer of enterprise-class, carrier-neutral, multi-tenant data center properties. The Company's data centers are generally purpose-built facilities with redundant power and cooling. The CyrusOne National IX Platform (the National IX Platform) delivers interconnection across states and between metro-enabled sites within its footprint and beyond. The Company has data centers in the United States, London and Singapore. As of December 31, 2016, the Company provided mission-critical data center facilities for 932 customers in 35 data centers and two recovery centers in 11 distinct markets (nine cities in the United States, London and Singapore) with approximately 3,904,000 net rentable square feet (NRSF). The Company provides round the clock security guard monitoring with customizable security features. As of December 31, 2016, the Company had approximately 1,657,000 NRSF under development.

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin-0.48%3.76%
Operating margin9.83%13.32%
EBITD margin-49.90%
Return on average assets-0.09%0.79%
Return on average equity-0.29%1.94%

Thursday, October 19, 2017

Atlassian (TEAM) reported earnings on Thur 19 Oct 2017 (a/h)

Atlassian Corporation Plc is an enterprise software company that develops products for software developers, project managers, and content management.
** charts after earnings **


Atlassian beats by $0.03, beats on revs; guides Q2 EPS above consensus, revs above consensus; raises FY18 guidance
  • Reports Q1 (Sep) earnings of $0.12 per share, excluding non-recurring items, $0.03 better thanthe Capital IQ Consensus of $0.09; revenues rose 41.7% year/year to $193.8 mln vs the $185.78 mln Capital IQ Consensus.
  • Co issues upside guidance for Q2, sees EPS of $0.12, excluding non-recurring items, vs. $0.10 Capital IQ Consensus Estimate; sees Q2 revs of $203-205 mln vs. $200.23 mln Capital IQ Consensus Estimate.
  • Co issues raised guidance for FY18, sees EPS of $0.46-0.47 from $0.42-0.44, excluding non-recurring items, vs. $0.44 Capital IQ Consensus Estimate; raises FY18 revs to $841-847 mln from $826-834 mln vs. $831.02 mln Capital IQ Consensus Estimate.
  • Atlassian ended the first quarter of fiscal 2018 with a total customer count on an active subscription or maintenance agreement basis of 107,746. Atlassian added 4,246 net new customers during the quarter.
  • Q2 Guidance: Gross margin is expected to be approximately 79% on an IFRS basis and approximately 84% on a non-IFRS basis. FY18 Guidance: Gross margin is expected to be approximately 79% on an IFRS basis and approximately 84% on a non-IFRS basis.


Atlassian Corporation Plc is a holding company. The Company offers a range of team collaboration products. The Company offers products, including JIRA, Confluence, HipChat, Bitbucket and JIRA Service Desk, for software developers, information technology (IT) managers and knowledge workers. The Company offers JIRA for team planning and project management; Confluence for team content creation and sharing; HipChat for team real-time messaging and communications; Bitbucket for team code sharing and management, and JIRA Service Desk for team service and support applications. JIRA allows teams to organize their work into projects and customize dashboards for those projects to keep their teams aligned and on track. Confluence provides a system for organizing, sharing and securing content in spaces arranged by team, project, department and others. The Company also offers additional tools for software developers, such as FishEye, Clover, Crowd, Crucible, Bamboo and SourceTree.

Key stats and ratios

Q3 (Sep '17)2017
Net profit margin-7.22%-6.86%
Operating margin-11.52%-10.18%
EBITD margin--0.25%
Return on average assets-4.27%-3.74%
Return on average equity-6.16%-5.23%

MongoDB (MDB) began trading on the Nasdaq on Thur 19 October 2017

The company was formerly known as 10gen, Inc. and changed its name to MongoDB, Inc. in August 2013.
  • Sector: Technology
  • Industry: Software - Application
  • Full Time Employees: 962
  • Founded in 2007 
  • Headquartered in New York, New York.

Corbus Pharma (CRBP) : mid-stage results for inflammatory disease drug

  • The drug, anabasum, is intended for the rare inflammatory condition dermatomyositis, which is associated with an itchy and painful rash and progressive muscle weakness, according to the Mayo Clinic. 

Corbus Pharma announces 'positive' topline results from its Phase 2 study of anabasum in dermatomyositis
  • The mean improvement (reduction) in the primary efficacy outcome, the Cutaneous Dermatomyositis Disease Area and Severity Index ("CDASI") activity score, a validated outcome measure of skin disease severity, was 9.3 points for anabasum treatment at the end of the study versus a reduction of 3.7 points for placebo treatment.
  • Anabasum also outperformed placebo in multiple secondary efficacy outcomes studied.

In the clinical trial, which enrolled 22 adults and lasted 16 weeks, the drug outperformed the placebo in the primary efficacy outcome and in multiple secondary efficacy outcomes, the company said. There were also no signs of safety issues, Corbus said. Currently, "we have little to offer patients with moderate to severe disease activity except immunosuppressive therapies with often limited efficacy and significant side effects," said Dr. Victoria Werth, a principal investigator in the study and a professor of dermatology at the Hospital of the University of Pennsylvania. Corbus Pharma shares have surged 6.9% over the last three months to $7.00 per share.

** charts day before  announcement **


=Laureate (LAUR) : 8-month performance

Del Taco (TACO) reported earnings on Thur 19 Oct 2017 (a/h)

** charts after earnings **


** monthly **

Del Taco reports EPS in-line, revs in-line; System-wide and Co-operated comparable restaurant sales growth of 4.1% and 3.7%; lowers FY17 EPS below consensus, narrows revs in-line
  • Reports Q3 (Sep) earnings of $0.13 per share, in-line with the Capital IQ Consensus of $0.13; revenues rose 6.3% year/year to $110.99 mln vs the $110.46 mln Capital IQ Consensus.
    • System-wide and Company-operated comparable restaurant sales growth of 4.1% and 3.7%. 
      • Company-operated comparable restaurant sales growth was comprised of average check growth of 4.0%, including approximately 1.5% of menu mix growth, partially offset by a transaction decline of 0.3%.
    • The opening of two company-operated and two franchise restaurants.
  • Co issues guidance for FY17, sees EPS of $0.52-$0.54 (prior: $0.52-0.55) vs. $0.56 Capital IQ Consensus Estimate; sees FY17 revs of $472-$475 mln (prior: $470-476 mln) vs. $472.65 mln Capital IQ Consensus Estimate.
    • Adjusted EBITDA between $71.5 million and $72.5 million (previously $71.5 and $73.5). 
    • Restaurant contribution margin between 19.5% and 19.8% (was 19.8% to 20.3%).
    • General and administrative expenses of between approximately 8.1% and 8.3% of total revenue (previously 8.2% and 8.4%).
    • Effective tax rate of approximately 39.0% (previously 40.0%).
    • Reaffirms net capital expenditures totaling approximately $43.0 million to $46.0 million. 
  • John D. Cappasola, Jr., President and Chief Executive Officer of Del Taco, commented, "During the third quarter, our company-operated and franchised restaurants both extended their track records of positive comparable restaurant sales, and The Del Taco system as a whole achieved 10.8% growth in comparable restaurant sales on a two-year stacked basis. We successfully executed our strategy to lap last year's accelerated performance by combining comprehensive improvement across the brand with an impactful marketing plan. We raised the bar in operations by focusing on improving our Overall Satisfaction Scores and Lunch and Dinner Speed compared to last year, embedding awareness and usage of The Del Taco and Platos, and reintroducing Carnitas as a limited time offer. We finished the quarter with our launch of Queso, a highly relevant and elevated QSR+ ingredient that is currently mixing at approximately 7% of sales and will enable exciting future product innovation across our menu."

Tuesday, October 17, 2017

Stitch Fix (SFIX) started trading on the Nasdaq on 17 October 2017

Stitch Fix is an online subscription and personal shopping service in the United States. 
  • Founded in 2011
  • Headquarters: San Francisco, CA
  • Founder and CEO: Katrina Lake; the youngest woman to take a company public

Stitch Fix Chief Executive Katrina Lake 

  • 10 days later:

Back in 2010, Lake tested the Stitch Fix concept for the first time in her apartment in Cambridge, Mass. while she was getting her business degree at Harvard Business School. The company officially launched in 2011, and six years later, the company -- which became profitable in 2014 -- now has over 5,700 employees and more than 3,400 stylists on staff, three offices, five warehouses and 10 remote styling hubs.

How Stitch Fix Works

The company has shipped millions of Fixes to date. Here’s what the smart-shopping process looks like.

1. Users fill out a 10- to 15-minute online or in-app Style Profile, indicating their fashion sensibilities, sizes, and budget.

2. An algorithm compares the customer’s preferences to Stitch Fix’s inventory of nearly 700 brands (plus the company’s 18 exclusive labels) and generates a list of items she’d be most likely to keep.

3. For a $20 styling fee (to be applied as a credit to any items that are kept), the list is assigned to one of Stitch Fix’s 3,400 personal stylists, who review the options against the shopper’s profile and choose five pieces to be sent. A note about how to style or accessorize the looks is included.

4. After receiving the box, the customer reviews each piece online, keeps what is wanted, and returns the rest. This data is logged on both the customer’s profile and the item, helping to better tailor future boxes to her taste.

Sunday, October 15, 2017

CVR Refining (CVRR) +50% (9-10/17)

Petroleum refining company
  • Headquarters: Sugar Land, TX
  • Founded: 2012
  • Parent organization: CVR Energy (CVI)


** weekly **

** monthly **

History of Dividends
Declared Ex-Dividend  Record Date PaymentPayout Amount


CVR Refining, LP is an independent downstream energy limited partnership with refining and related logistics assets that operates in the mid-continent region. The Company is a petroleum refiner. It owned and operated a complex full coking medium-sour crude oil refinery in Coffeyville, Kansas with a rated capacity of 115,000 barrels per calendar day (bpcd) and a complex crude oil refinery in Wynnewood, Oklahoma with a rated capacity of 70,000 bpcd capable of processing 20,000 bpcd of light sour crude oils (within its rated capacity of 70,000 bpcd), as of December 31, 2016. In addition, it also controlled and operated supporting logistics assets, including approximately 340 miles of active owned and leased pipelines, approximately 150 crude oil transports, a network of crude oil gathering tank farms, approximately 6.4 million barrels of owned and leased crude oil storage and over 4.5 million barrels of combined refined products and feedstocks storage capacity, as of December 31, 2016.

Key stats and ratios

Q2 (Jun '17)2016
Net profit margin-1.43%0.35%
Operating margin-0.55%1.76%
EBITD margin-4.67%
Return on average assets-3.20%0.68%
Return on average equity-5.69%1.19%

Friday, October 13, 2017

Tandem Diabetes Care (TNDM) : commences offering of its common stock, Series A warrants and Series B warrants

** daily **

** monthly **

Tandem Diabetes Care announces the pricing of an underwritten public offering of common stock and warrants for gross proceeds of approx. $16.2 mln
  • Announces the pricing of an underwritten public offering of (i) 4,630,000 shares of its common stock, (ii) Series A warrants to purchase 4,630,000 shares of its common stock and (iii) Series B warrants to purchase 4,630,000 shares of its common stock, for gross proceeds of approximately $16.2 million, at a public offering price of $3.50 per share and accompanying warrants. The Series A warrants have an exercise price of $3.50 per share, are immediately exercisable and will expire on the fifth anniversary of the date of issuance. The Series B warrants have an exercise price of $3.50 per share, are immediately exercisable and will expire on the six-month anniversary of the date of issuance. The shares of common stock and the warrants will be immediately separable and will be issued separately. All of the shares of common stock and warrants to be sold in the offering are being offered by Tandem.
  • Tandem intends to use the net proceeds from the proposed offering for working capital and other general corporate purposes. The offering is expected to close on or about October 17, 2017, subject to customary closing conditions.

Tandem Diabetes Care sees Q3 revs above consensus 
  • Co issues upside guidance for Q3 (Sep), sees Q3 (Sep) revs of $26.5-27.5 mln vs. $26.24 mln Capital IQ Consensus Estimate. 
  • The Technology Upgrade Program expired as of September 30, 2017 and more than 2,500 people participated in the Program since its inception in July 2016.
  • "Hurricanes Harvey and Irma adversely impacted the normal business activities of our sales force, distributors, healthcare providers and potential customers in Texas, Florida and other impacted regions. For instance, the daily inflow to the insurance verification and approval portion of our sales pipeline decreased in early September compared to August, which coincided with the hurricanes. We also experienced a measurable decrease in our sequential monthly pump shipments for the Gulf Coast region for the month of September as compared to the month of August, whereas for all other sales regions we saw either relatively stable volumes or increases in monthly pump shipments for the month of September as compared to the month of August. In addition, we have two independent distributors located within the affected areas that experienced operational disruptions during the periods around the time of the hurricanes."
  • Q4 Guidance: "We expect our share of the United States insulin pump market will be approximately 11% at the end of 2017, based on 2015 estimates of the United States insulin pump market by Close Concerns, Inc., an independent consulting and publishing company that provides diabetes advisory services...Historically, we have experienced product shipments and sales being weighted heavily towards the second half of the year, with the highest percentage of product shipments and sales occurring in the fourth quarter of the year. For instance, excluding 2016 when we experienced an unusual sales pattern and implemented our Technology Upgrade Program, in a typical year, our sales for the fourth quarter have ranged from approximately 35% to 38% of the total sales for the full year. We expect seasonality will have a similar impact on our sales in 2017, excluding approximately $3.5 million of deferred sales and upgrade fees received associated with our Technology Upgrade Program that we expect to recognize in the third quarter."